Matt Gline landed Roivant Sciences, the drug firm founded by former GOP presidential candidate Vivek Ramaswamy, one of biotech’s biggest deals last year. In October, the company sold its experimental therapy for inflammatory bowel disease, RVT-3101, to Roche for at least $7.1 billion, having spent $50 million less than a year earlier acquiring the drug from Pfizer and investing in it for future late-stage trials. The deal put Gline on STAT’s list of the best biopharma CEOs of 2023. At the J.P. Morgan Healthcare Conference that kicked off 2024, Roivant’s business development team was already in search of the next big thing, meeting with pharmaceutical companies about existing drugs in their pipeline that they might be willing to hand off to Roivant to further develop.
Industry
Location
-
New York, N.Y.
